Establishment and validation of a nomogram for estimating the overall survival of vulvar squamous cell carcinoma patients aged 50 years or older

This study aimed to develop a nomogram for estimating the overall survival (OS) of vulvar squamous cell carcinoma patients aged ≥50 years based on their clinicopathological characteristics. The Surveillance, Epidemiology and End Results (SEER) database was searched for cases diagnosed with vulvar squamous cell carcinoma from 2000 to 2019. They were randomly grouped into a training and a test cohort in a 7:3 ratio. Cox regression analyses were performed to identify risk factors associated with the overall survival rate of the patients. Then, the nomogram was built based on independent factors selected by the minimum Akaike Information Criterion (AIC) value in multivariate Cox regression analyses. The performance of the nomogram was assessed by its concordance index (C-index) and the area under curve (AUC). Its predictive power was determined by calibration plot and clinical applicability by decision curve analysis (DCA). A total of 3048 patients were identified and randomized into the training (n = 2146) and validation (n = 902) cohort. The validation indicated that the nomogram had good recognition ability for clinical trials, patient counseling, and rationalizing therapeutic modalities. The C-index for OS rates was 0.729 (95%Confidence Interval (CI): 0.715–0.743) in the training cohort and 0.717 (95% CI: 0.693–0.741) in the validation cohort. The AUCs of the 1-, 3- and 5-year OS were 0.789, 0.781 and 0.775 in the training cohort and 0.815, 0.772 and 0.748 in the validation cohort. Calibration plots showed that the nomogram had good predictive power, and DCA demonstrated that the proposed nomogram could provide a net clinical benefit. Our nomogram demonstrated promising accuracy in comprehensively predicting the OS of elderly vulvar squamous cell carcinoma patients. It could be used as a reference to guide individualized treatments and plan the follow-up of elderly patients with vulvar squamous cell carcinoma.

Overall survival; Prognosis; Nomogram; Vulvar squamous cell carcinoma; SEER

[1] Virarkar M, Vulasala SS, Daoud T, Javadi S, Lall C, Bhosale P. Vulvar cancer: 2021 revised FIGO staging system and the role of imaging. Cancers. 2022; 14: 2264.

[2] Pedrão PG, Guimarães YY, Godoy LR, Possati-Resende JC, Bovo AC, Andrade CEMC, et al. Management of early-stage vulvar cancer. Cancers. 2022; 14: 4184.

[3] Chow L, Tsui BQ, Bahrami S, Masamed R, Memarzadeh S, Raman SS, et al. Gynecologic tumor board: a radiologist’s guide to vulvar and vaginal malignancies. Abdominal Radiology. 2021; 46: 5669–5686.

[4] Merlo S. Modern treatment of vulvar cancer. Radiology and Oncology. 2020; 54: 371–376.

[5] Mix JM, Gopalani SV, Simko S, Saraiya M. Trends in HPV- and non-HPV-associated vulvar cancer incidence, United States, 2001–2017. Preventive Medicine. 2022; 164: 107302.

[6] Ouh Y, Kang D, Kim H, Lee JK, Hong JH. Prevalence and treatment of vulvar cancer from 2014–2018: a nationwide population-based study in Korea. Journal of Korean medical science. 2022; 37: e25.

[7] Weinberg D, Gomez-Martinez R. Vulvar cancer. Obstetrics and Gynecol-ogy Clinics. 2019; 46: 125–135.

[8] Serrado MA, Horta M, Cunha TM. State of the art in vulvar cancer imaging. Radiologia Brasileira. 2019; 52: 316–324. (In Portuguese)

[9] Olawaiye AB, Cuello MA, Rogers LJ. Cancer of the vulva: 2021 update. International Journal of Gynecology & Obstetrics. 2021; 155: 7–18.

[10] Deng CG, Lv Y, Yan H, Sun DC, Qu TT, Pan YT, et al. Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer. BMC Cancer. 2021; 21: 1227.

[11] Xiao R, Liu C, He W, Ma L. Prognostic factors and a nomogram predicting overall survival and cancer-specific survival for patients with collecting duct renal cell carcinoma. BioMed Research International. 2021; 2021: 1–15.

[12] Rouzier R, Preti M, Haddad B, Martin M, Micheletti L, Paniel B. Development and validation of a nomogram for predicting outcome of patients with vulvar cancer. Obstetrics & Gynecology. 2006; 107: 672–677.

[13] Lei L, Tan L, Zhao X, Zeng F, Xu D. A prognostic nomogram based on lymph node ratio for postoperative vulvar squamous cell carcinoma from the surveillance, epidemiology, and end results database: a retrospective cohort study. Annals of Translational Medicine. 2020; 8: 1382.

[14] Mao Y, He M, Tang Z, Chen M, Wu L, Liang T, et al. Prognostic nomograms to predict overall survival and cause specific death in vulvar squamous cell carcinoma. International Journal of Gynecologic Cancer. 2022; 32: 706–715.

[15] Liu J, Wang M. Development and validation of nomograms predicting cancer-specific survival of vulvar cancer patients: based on the surveillance, epidemiology, and end results program. International Journal of Gynecology & Obstetrics. 2022; 156: 529–538.

[16] Scampa M, Kalbermatten DF, Oranges CM. Squamous cell carcinoma of the vulva: a survival and epidemiologic study with focus on surgery and radiotherapy. Journal of Clinical Medicine. 2022; 11: 1025.

[17] Pan X, Yang W, Chen Y, Tong L, Li C, Li H. Nomogram for predicting the overall survival of patients with inflammatory breast cancer: a SEER-based study. The Breast. 2019; 47: 56–61.

[18] Hellman K, Holmberg E, Bjurberg M, Borgfeldt C, Dahm-Kähler P, Flöter Rådestad A, et al. Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: a population-based SweGCG study. Gynecologic Oncology. 2020; 159: 663–671.

[19] Rottmann M, Beck T, Burges A, Dannecker C, Kiechle M, Mayr D, et al. Trends in surgery and outcomes of squamous cell vulvar cancer patients over a 16-year period (1998–2013): a population-based analysis. Journal of Cancer Research and Clinical Oncology. 2016; 142: 1331–1341.

[20] Hami LT, Lampe B, Mallmann P, Forner DM. The impact of age on the prognosis of vulvar cancer. Oncology Research and Treatment. 2018; 41: 520–524.

[21] Prieske K, Woelber L, Muallem MZ, Eulenburg C, Jueckstock JK, Hilpert F, et al. Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC)—analysis of the AGO-CaRE-1 study. Gynecologic oncology. 2021; 161: 442–448.

[22] Chen J, Ln H. A review of prognostic factors in squamous cell carcinoma of the vulva: evidence from the last decade. Seminars in Diagnostic Pathology. 2020. [Preprint].

[23] Zapardiel I, Iacoponi S, Coronado PJ, Zalewski K, Chen F, Fotopoulou C, et al. Prognostic factors in patients with vulvar cancer: the VULCAN study. International Journal of Gynecological Cancer. 2020; 30: 1285–1291

[24] Karataşlı V, Erkılınç S, Çakır İ, Can B, Karadeniz T, Gökçü M, et al. The effect of lymph node metastasis on overall survival and disease-free survival in vulvar cancer patients. Ginekologia Polska. 2020; 91: 62–67.

[25] Serre E, Diguisto C, Body G, Raimond E, Bendifallah S, Touboul C, et al. Prognostic significance of groin lymph node ratio in vulvar squamous cell carcinoma. Gynecologie, Obstetrique, Fertilite & Senologie. 2020; 48: 729–735.

[26] Eva LJ, Sadler L, Fong KL, Sahota S, Jones RW, Bigby SM. Trends in HPV-dependent and HPV-independent vulvar cancers: the changing face of vulvar squamous cell carcinoma. Gynecologic Oncology. 2020; 157: 450–455.

[27] Eva L, Sadler L, Thompson J, Sahota S, Fong KL, Jones RW, et al. HPV-independent and HPV-associated vulvar squamous cell carcinoma: two different cancers. International Journal of Gynecologic Cancer. 2022; 32: 1108–1114.